Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, Siccardi A G
Department of Nuclear Medicine, Istituto Scientifico H. San Raffaele, Sorin Biomedica, Università di Milano, Italy.
Eur J Nucl Med. 1992;19(5):322-9. doi: 10.1007/BF00177053.
A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3-5 days later by 100-150 micrograms of indium-111 streptavidin, at the specific activity of 280-370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1-8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1-30:1) and 45:1 (range 12:1-120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1-30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01-0.3) for recurrences and 0.05 for primary tumour (range 0.005-0.2). Over 24-48 h 14% i.d. (range 8-18% i.d.) was found in the urine, 14% i.d. (range 6-29% i.d.) in the blood and 63% i.d. (range 56-70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.
本文描述了一种使用生物素化单克隆抗体（MoAb）和放射性链霉亲和素进行卵巢癌腹腔内肿瘤靶向治疗的新方法。15例经组织学确诊的卵巢癌患者腹腔内注射2mg生物素化MoAb MOv18，3 - 5天后，在500ml生理盐水中注射100 - 150μg铟 - 111链霉亲和素，比活度为280 - 370MBq/mg。未观察到毒性反应。在放射性注射后2至48小时，通过记录平面和单光子发射断层扫描（SPET）数据对肿瘤进行成像。所有患者在扫描后1 - 8天（平均3天）接受手术。测量切除的肿瘤和正常组织的放射性。手术当天，腹腔内和腹腔外样本的肿瘤与正常组织比值分别为9:1（范围3:1 - 30:1）和45:1（范围12:1 - 120:1）。肿瘤与血液的平均比值为14:1（范围4:1 - 30:1）。复发肿瘤每克的注射剂量（i.d.）为0.112（范围0.01 - 0.3），原发性肿瘤为0.05（范围0.005 - 0.2）。在24 - 48小时内，尿液中发现14% i.d.（范围8 - 18% i.d.），血液中为14% i.d.（范围6 - 29% i.d.），63% i.d.（范围56 - 70% i.d.）仍在腹腔内。这些初步临床数据表明，这种两步策略在卵巢癌腹腔内放射免疫定位和放射免疫治疗方面可能优于传统方法（放射性标记抗体）。
